About US
Contact us
-
Surge raises $26M to take anti-cancer extended-release hydrogel into the clinicSurge Therapeutics hasraisedmoney to take its extended-release biodegradable hydrogel into the clinic, reeling in $26 million to test its belief that implanting the scaffolds after surgery will impro2022/10/17
-
Novartis' Sandoz sells Chinese finished drugs plant to CDMO Jiuzhou for $15.1MEven as Novartis works to separate Sandoz, the Swiss parent hasn’t stopped making deals for the outgoing generics subsidiary. Chinese CDMO Jiuzhou Pharmaceutical said it plans to buy a Sa2022/10/14
-
Asymchem Labs in early planning for $697M manufacturing facility in ChinaAsymchem Labs, a Chinese CDMO, is in the early phases ofplanning(PDF) a 4 billion Chinese yuan to 5 billion Chinese yuan ($557 million to $697 million) manufacturing campus on the outskirts of Shangh2022/10/14
-
WuXi's expansion tear rolls on with new high-potency oral production facilityWuXi STA, a subsidiary of WuXi AppTec,continued its expansion march with theopeningof the Chinese CDMO’s first high-potency oral drug production plant located on the WuXi City campus near Shanghai.2022/10/12
-
Daiichi Sankyo bags an industry first with Japanese nod for blood cancer drug EzharmiaWhile Daiichi Sankyo has been focusing on a stable of antibody-drug conjugates, the Japanese company has won a global first in an area that Pfizer is also targeting. Daiichi Sankyo has wo2022/10/12
-
Fierce Pharma Asia—Astellas-Seagen, Eisai-Merck, BeiGene-Novartis, Hengru share new cancer data at ESMOAt ESMO congress 2022, Seagen, Astellas and Merck showed how Padcev and Keytruda contributed to a combo in previously untreated bladder cancer. Three sets of liver cancer data by Merck and Eisai, Bei2022/10/10
-
Fierce Pharma Asia—Moderna's Japan plan; Takeda's cancer deal with Puma; Everest's new CEOModerna is considering building a manufacturing plant in Japan, its CEO says.Takeda has offloaded an unwanted cancer drug to Puma Biotechnology. Everest Medicines has hired former Gilead China head2022/10/10
-
Emergent wraps up purchase of Chimerix's potential monkeypox treatment TembexaWith the monkeypox virus evolving—just as the coronavirus before it—adding new products to combat its spread is a key priority for the U.S. Monday, Emergent BioSolutions took a step towar2022/9/29
-
COVID-19 tracker: BioNTech, Pfizer challenge two CureVac patents in EuropeCureVac's patent showdown with Pfizer and BioNTech has taken another turn. Plus, Merck inked a deal to expand the reach of its Ridgeback-partnered antiviral. Please read below for the lat2022/9/29
-
Eli Lilly hit with another age discrimination lawsuit—this time from a federal agencyAge discrimination lawsuits have been cropping up around the industry in recent years, and Eli Lilly is no stranger to such claims. Now, the company is defending against age discrimination allegation2022/9/27